Clinical trial
A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
NCT06431373 is registered in ClinicalTrials.gov with Priovant Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
- Lead sponsor
- Priovant Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- September 11, 2024
- Completion date
- February 1, 2028
- Enrollment
- 371 (actual)
- Sites
- 107
Conditions
As the registry lists them; a condition with its own page is linked.